As a two-sided platform for pre-approval treatment access, myTomorrows serves the interests of both patients and drug developers. On one side, the company helps patients to obtain emerging therapies when approved treatments and other clinical trials have been ruled out.
On the other side, the company acts as a strategic operating partner to drug companies for expanded access administration and real-world data collection. The following attributes summarize myTomorrows’ approach: Patient-first approach, awareness activities, quality management system, Real-world data, regulatory support and pre-approval reimbursement.
This results in meaningful expanded access programs with the goal to benefit more patients, better serve treating physicians and helping industry achieve their goals.